GCG and type 1 diabetes mellitus: Next, we conducted a single-centre, randomised, triple crossover, phase 2a superiority trial in people with T1D to evaluate the effectiveness of oral glibenclamide (0.3, 0.6, and 3 mg/day, over 14-18 days per dose) or an acute single dose of dapagliflozin (10 mg) in restoring glucagon counter-regulation.